Skip to main content
Premium Trial:

Request an Annual Quote

EraGen, Emory to Develop Genotyping System to Combat HIV Drug Resistance

NEW YORK, March 23 (GenomeWeb News) - EraGen Biosciences said yesterday that it has entered into a collaborative agreement with Emory University to develop a genotyping system to detect drug-resistant HIV variants.

The project, supported by a $350,000 Small Business Technology Transfer grant from the National Institutes of Health, will develop a system to detect HIV mutations at an early stage, allowing physicians to optimize treatment before the virus is fully drug-resistant, EraGen said.

EraGen will provide Emory with its EraGen Real-Time PCR Assay, an RT-PCR method to detect and quantitate mixed populations of closely related viral sequences. According to EraGen, the method is able to detect one copy of mutant per 10,000 wild-type RNA copies in a reaction containing 15 million total target molecules.

The company said it plans to optimize the system to detect and quantitate 17 antiretroviral-resistant HIV mutations, which confer resistance to nucleoside inhibitors of reverse transcriptase, non-nucleoside RT inhibitors, and protease inhibitors.

EraGen said it would build on prototype systems it has already developed for quantitative resistance screening to the HIV therapeutics Viread, Emtriva, and Comitia.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.